Hvilken er prisen på Freeline Therapeutics Holdings plc (FRLN)

Prisen på Freeline Therapeutics Holdings plc (FRLN) er $6.48

Hva er markedsverdien på Freeline Therapeutics Holdings plc (FRLN)

Markedsverdien på Freeline Therapeutics Holdings plc (FRLN) er $15.41M

Freeline Therapeutics Holdings plc (FRLN) P/S-forhold

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

År	P/S-forhold	Endre
Ikke nok data for de angitte datoene.

År

P/S-forhold

Endre

Ikke nok data for de angitte datoene.

Selskap	P/S-forhold	Forskjell i P/S-forhold	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	4.74	-	BE

Selskap

P/S-forhold

Forskjell i P/S-forhold

Land